Despite the current study having inherent weaknesses in low sample size and lack of validation in a wider population, the results do highlight the importance of transcriptional profiling of HER2+ and HER2− CRC patients in identifying potential biomarkers that play a role in CRC pathogenesis. The gene discussed is ERBB2; the disease is colorectal carcinoma.